Literature DB >> 18382628

Tumour necrosis factor inhibitors and infection: What is there to know for infectious diseases physicians?

Bl Johnston1, Jm Conly.   

Abstract

Entities:  

Year:  2006        PMID： 18382628      PMCID： PMC2095075          DOI： 10.1155/2006/385789

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN： 1712-9532            Impact factor:   2.471


× No keyword cloud information.
  35 in total

1.  Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate.

Authors:  J M van der Klooster; R J Bosman; H M Oudemans-van Straaten; J I van der Spoel; J P J Wester; D F Zandstra
Journal:  Intensive Care Med       Date:  2003-11-05       Impact factor: 17.440

2.  High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy.

Authors:  William S Mow; Maria T Abreu-Martin; Konstantinos A Papadakis; Howard E Pitchon; Stephan R Targan; Eric A Vasiliauskas
Journal:  Clin Gastroenterol Hepatol       Date:  2004-04       Impact factor: 11.382

3.  Fatal case of protothecosis in a hematopoietic stem cell transplant recipient after infliximab treatment for graft-versus-host disease.

Authors:  Jad A Khoury; Eric R Dubberke; Steven M Devine
Journal:  Blood       Date:  2004-11-15       Impact factor: 22.113

Review 4.  Immunosuppression related to collagen-vascular disease or its treatment.

Authors:  Carol Dukes Hamilton
Journal:  Proc Am Thorac Soc       Date:  2005

5.  Efficacy and safety of the anti-TNF biologic agents.

Authors:  Arthur L Weaver
Journal:  Mod Rheumatol       Date:  2004       Impact factor: 3.023

Review 6.  Infections associated with tumor necrosis factor-alpha antagonists.

Authors:  David J Rychly; Joseph T DiPiro
Journal:  Pharmacotherapy       Date:  2005-09       Impact factor: 4.705

Review 7.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Authors:  Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori
Journal:  JAMA       Date:  2006-05-17       Impact factor: 56.272

8.  Reactivation of latent granulomatous infections by infliximab.

Authors:  Robert S Wallis; Michael Broder; John Wong; Albert Lee; Lalima Hoq
Journal:  Clin Infect Dis       Date:  2005-08-01       Impact factor: 9.079

9.  Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?

Authors:  Stefan Ehlers
Journal:  Clin Infect Dis       Date:  2005-08-01       Impact factor: 9.079

10.  Granulomatous infectious diseases associated with tumor necrosis factor antagonists.

Authors:  R S Wallis; M S Broder; J Y Wong; M E Hanson; D O Beenhouwer
Journal:  Clin Infect Dis       Date:  2004-04-15       Impact factor: 9.079
View more
  9 in total

1.  Alemtuzumab and natalizumab: the monoclonal antibody story continues.

Authors:  Bl Johnston; Jm Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-11       Impact factor: 2.471

2.  Cytokine TNF-α and its receptors TNFRI and TNFRII play a key role in the in vitro proliferative response of BLV infected animals.

Authors:  Pamela Anahí Lendez; Lucía Martinez-Cuesta; María Victoria Nieto Farias; Guillermina Laura Dolcini; María Carolina Ceriani
Journal:  Vet Res Commun       Date:  2021-08-27       Impact factor: 2.459

3.  Characterization of Iturin V, a Novel Antimicrobial Lipopeptide from a Potential Probiotic Strain Lactobacillus sp. M31.

Authors:  Shelley Sardul Singh; Md Naushad Akhtar; Deepika Sharma; Santi M Mandal; Suresh Korpole
Journal:  Probiotics Antimicrob Proteins       Date:  2021-05-13       Impact factor: 4.609

4.  Honey Bee Pollen in Meagre (Argyrosomus regius) Juvenile Diets: Effects on Growth, Diet Digestibility, Intestinal Traits, and Biochemical Markers Related to Health and Stress.

Authors:  Valentina Panettieri; Stavros Chatzifotis; Concetta Maria Messina; Ike Olivotto; Simona Manuguerra; Basilio Randazzo; Andrea Ariano; Fulvia Bovera; Andrea Santulli; Lorella Severino; Giovanni Piccolo
Journal:  Animals (Basel)       Date:  2020-01-31       Impact factor: 2.752

5.  Sildenafil Citrate Influences Production of TNF-α in Healthy Men Lymphocytes.

Authors:  Michał Zych; Aleksander Roszczyk; Monika Kniotek; Beata Kaleta; Radoslaw Zagozdzon
Journal:  J Immunol Res       Date:  2019-10-22       Impact factor: 4.818

6.  Developing Rapid Antimicrobial Susceptibility Testing for Motile/Non-Motile Bacteria Treated with Antibiotics Covering Five Bactericidal Mechanisms on the Basis of Bead-Based Optical Diffusometry.

Authors:  Yao-Tzu Yang; Jhih-Cheng Wang; Han-Sheng Chuang
Journal:  Biosensors (Basel)       Date:  2020-11-19

7.  Distinct Role of TNFR1 and TNFR2 in Protective Immunity Against Orientia tsutsugamushi Infection in Mice.

Authors:  Yuejin Liang; James Fisher; Casey Gonzales; Brandon Trent; Galen Card; Jiaren Sun; Alexei V Tumanov; Lynn Soong
Journal:  Front Immunol       Date:  2022-04-11       Impact factor: 8.786

8.  Small-molecule screening identifies Syk kinase inhibition and rutaecarpine as modulators of macrophage training and SARS-CoV-2 infection.

Authors:  Sinu P John; Anju Singh; Jing Sun; Makheni Jean Pierre; Lulwah Alsalih; Crystal Lipsey; Ziann Traore; Shenavia Balcom-Luker; Clinton J Bradfield; Jian Song; Tovah E Markowitz; Margery Smelkinson; Marc Ferrer; Iain D C Fraser
Journal:  Cell Rep       Date:  2022-09-15       Impact factor: 9.995

9.  Bioactive Diterpenes, Norditerpenes, and Sesquiterpenes from a Formosan Soft Coral Cespitularia sp.

Authors:  You-Cheng Lin; Chi-Chien Lin; Yi-Chia Chu; Chung-Wei Fu; Jyh-Horng Sheu
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.